\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
TAIZHOU, China, Aug. 3, 2022 /PRNewswire/ — Jiangsu Recbio Technology Co. , Ltd. (The “Company” and its subsidiaries, the “Group,” inventory code: 02179. HK) is pleased to announce that Start the Company recently obtained clinical trial approval for its recombinant COVID-19 protein vaccine, ReCOV, from the Philippine Food and Drug Administration, authorizing the company to conduct a randomized, blinded, actively controlled Phase II clinical trial of ReCOV in healthy subjects 18 years of age or older who have gained a primary vaccination with two doses of an inactivated COVID-19 vaccine to compare immunogenicity and protection between ReCOV and Pfizer’s COMIRNATY® mRNA vaccine. The Company plans to begin clinical recruitment in the near future.
ReCOV is a recombinant COVID-19 vaccine developed through the Company with its generation platforms, adding new protein engineering platforms and adjuvants, and the adjuvant used is the new self-evolved BFA03 adjuvant through the Company. Based on applicable studies conducted through the Company, ReCOV would possibly induce superior neutralizing antibody titers and biased Th1 cellular immune responses, and has demonstrated a favorable neutralizing effect and immunological patience as opposed to variants adding the Omicron variant and the Delta variant. It has a variety of comprehensive advantages, adding a positive overall profile protection, possible expansion in production scale, low production cost, preparation ability, and the ability to be stored and transported at room temperature.
About Recbio
Founded in 2012, Recbio is a cutting-edge vaccine company. With the vision of “Becoming the leader in cutting-edge vaccines in the future”, Recbio’s project is “Protecting human fitness with best-in-class vaccines”. It has established 3 primary generation platforms, adding a new adjuvant platform, a protein engineering platform, an immunological assessment platform, and an mRNA vaccine platform. vaccine candidates, tuberculosis vaccine candidates for adults, and more. The senior control team has more than 20 years of experience in the development and commercialization of state-of-the-art vaccines. For more information, visit https://www. recbio. cn/.
Forward-Looking Statements
This presentation would possibly involve projections, estimates, forecasts, objectives, reviews, clients, effects, functionality and forward-looking statements related to the monetary condition, effects of operations, capital position, strategy and activities of the Group that may be known through the use of futures. aspect terminology such as “possibly”, “will”, “deserve”, “expect”, “anticipate”, “project”, “plan”, “estimate”, “seek”, “intend”, “target”, “believe” “, “potential” and “reasonably possible” or their negative bureaucracy or other diversifications or comparable terminology (collectively, “forward-looking statements”), aggregating strategic priorities, studies and progression plans, and any monetary investment, and capital objectives and all the other objectives, commitments and ambitions described in writing or orally in this document. These forward-looking statements are not a reliable indicator of long-term performance, as they may involve vital assumptions, expressed or implied, and subjective judgments that may or may not be correct, accurate or complete. There can be no guarantee that any of the matters set forth in the forward-looking statements will be feasible, will happen or will be learned or is complete or accurate. The assumptions and judgments could possibly turn out to be incorrect, erroneous or incomplete, and would involve known and unknown risks, uncertainties, contingencies and other significant actors, many of which are beyond the control of the Group. There is also no guarantee that the Group will be able to effectively expand or commercialize its main products or other candidates under development. Actual achievements, effects, functionality or other long-term events or situations may differ materially from those stated, implied and/or reflected in forward-looking statements due to a variety of risks, uncertainties and other matters (including, without limitation, general market situations, regulatory changes, geopolitical tensions or limitations and modifications of knowledge). These forward-looking statements are based on the Group’s beliefs, expectations and reviews as of the date the statements are made, and the Group does not assume, and hereby disclaims, any legal duty or responsibility to update, revise or supplement them. whether cases or management’s beliefs, expectations, or reviews merit change. For these reasons, you deserve not to rely on any forward-looking statements and you are expressly cautioned not to rely on them. No representation or warranty, express or implied, is made by or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, clients or performance involved in this document.
Please refer to the company’s listings on The Stock Exchange of Hong Kong Limited (www. hkexnew. hk) or the Company (www. recbio. cn) for more details. In the event of a discrepancy between this Submission and the ads, the ads will prevail.
Jiangsu Recbio Technology Co. , Limited.
Investor application: E-mail: ir@recbio. cnTel: 86-0523-86818860
Media Request: Email: media@recbio. cnTel: 86-0523-86818860
Related links: https://www. recbio. cn/
SOURCE Jiangsu Recbio Technology Co. , Ltd.